The Asia-Pacific continuous glucose monitoring market is expected to register a CAGR of more than 20% during the forecast period. The countries in Asia-Pacific have a high prevalence of diabetes. According to IDF, in 2019, approximately 2 million deaths were attributed directly to diabetes in Asia-Pacific. An additional 1.2 million deaths were caused due to high blood glucose, in 2019. The countries in the Asia-Pacific region account for close to 60% of the total diabetic population in the world, since the prevalence of diabetes in these countries is consistently showing increasing trends.
Key Market Trends
CGMs Prove to Be an Instrumental Tool that May Help in Maintaining the Glycemic Balance
The prevalence among the adult population, aged between 20 and 70 years, is anticipated to rise from 285 million, in 2010, to a staggering 438 million by 2030. In patients relying on insulin pumps or multiple daily injection (MDI) therapy, the CGM proves to be an instrumental tool that helps in the improvement of glycemic balance without aggregating the danger for severe hypoglycemia. As studied in several clinical trials, diabetic patients with T1DM have been shown to have better glycemic control, as compared to when glucometer is used for routine self-monitoring blood glucose. The trend follows even in children who use CGM in a steady fashion. The results in these children show better-glycosylated hemoglobin (HbA1c) levels without an amplified frequency of hypoglycemia. The current, approved CGM models administer glucose oxidase-based electrochemical subcutaneous sensors for the detection of glucose levels in interstitial fluid.
China Held the Highest Market Share in the Asia-Pacific Continuous Glucose Monitoring Market in 2019
In the Asia-Pacific continuous glucose monitoring market, China accounted for close to 26% of the market share in 2019. China registered 48,000 new Type-1 cases in 019. As CGM is mostly used by Type-1 diabetes patients, it is estimated that the CGM market in China will reach USD 95 million by the end of 2025. Japan held the second-highest market share in 2019, and it is expected to register a CAGR of about 20.2% during the forecast period. It is imperative that the CGM devices are used alongside insulin pumps, and as the trends show a higher number of diabetic patients using insulin pumps for diabetes management, it can be predicted that the number of units of CGM devices sold may also follow.
The Asia-Pacific continuous glucose monitoring market is highly consolidated. Dexcom, Medtronic, and Abbott held more than 60% of the market share in 2019. Some of the recent developments in the market were:
- In February 2019, Terumo Corporation, a Tokyo-based company, announced its plans to sell the Dexcom G4 PLATINUM Continuous Glucose Monitoring System in Japan.
- In 2019, Handok signed an agreement with Medtronic Korea to market and distribute two continuous glucose monitoring (CGM) devices, namely, Guardian Connect and iPro 2, to local medical institutions.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support